April 9, 2020
March 13, 2020
With the growing concerns regarding COVID-19 (“coronavirus”) across Canadian communities and the world, we want to provide an update on the Defeat Duchenne Family Forum scheduled for Saturday, May 2, 2020, in Montréal, Québec at Shriners Hospitals for Children – Canada. Jesse’s Journey and La Force will be postponing the event until later in the […]
February 27, 2020
Did you know approximately 1 in 12 Canadians, two-thirds of them children, are affected by a rare disease? Saturday, February 29, 2020, is Rare Disease Day, and we ask for your help in raising awareness of Duchenne muscular dystrophy. Though Duchenne is the most common fatal genetic disorder diagnosed in childhood, it is considered a […]
January 28, 2020
2020 is an exciting year for Jesse’s Journey as we celebrate our past and ignite a bold new vision for our future. This year marks the 25th anniversary of the organization as our founder, John Davidson, set out on an incredible mission to push his son, Jesse, across Ontario in his wheelchair – a trek of 3,339 […]
March 30, 2020
Catabasis has shared its March 2020 update: Catabasis provided an update regarding COVID-19 and Duchenne, FAQ’s, and shared the presentation slides from the MDA Virtual Clinical Trials Session. March 2020 – Catabasis Connection Issue 25 Edasalonexent Update: In Duchenne, the loss of dystrophin leads to chronic activation of NF-kB, which is a key driver of […]
March 24, 2020
Santhera Pharmaceuticals shared its 2019 Annual Results and Highlights Piepleine Progress for Duchenne muscular dystrophy. “Santhera is emerging as a leader in addressing rare neuromuscular diseases and 2019 saw us prepare the business for several significant value inflection points this year for our drug candidatesto treat DMD,” said Dario Eklund, CEO of Santhera. “The regulatory […]
March 12, 2020
Registration is now open for the 2020 Walk to Defeat Duchenne presented by Sbenati Dentistry. Gather your friends and family, create a team, and register for the event in London, Ontario or host your own Walk anywhere in Canada on Sunday, May 24, 2020. Help raise awareness and vital funds to further the mission to #defeatduchenne. […]
March 12, 2020
Solid Biosciences Inc. has provided an update on the IGNITE DMD phase I/II microdystrophin gene therapy clinical program. As previously reported in late 2019, the IGNITE DMD clinical program was placed on hold. Today, they announced the biomarker data from the third patient dosed in the 2E14 vg/kg dose cohort of IGNITE DMD, including three-month […]
February 28, 2020
Catabasis has shared its February 2020 update: “February is all about the heart and that’s a big focus for us, too! Because the cardiac function is so vital to those affected by Duchenne, we’re passionate to learn more about the heart and edasalonexent in our Phase 3 PolarisDMD trial. In young boys affected by Duchenne, […]
February 3, 2020
Jesse’s Journey is proud to represent the Duchenne community in the new neuromuscular network for Canada, NMD4C (NMD for Canada). The neuromuscular network for Canada brings together the country’s leading clinical, scientific, technical and patient expertise to improve care, research and collaboration in neuromuscular disease. Launched in January 2020 with funding from the Canadian Institutes of Health […]
